PH27203A - A pharmaceutical preparation in the treatment of tonsilitis - Google Patents
A pharmaceutical preparation in the treatment of tonsilitis Download PDFInfo
- Publication number
- PH27203A PH27203A PH40021A PH40021A PH27203A PH 27203 A PH27203 A PH 27203A PH 40021 A PH40021 A PH 40021A PH 40021 A PH40021 A PH 40021A PH 27203 A PH27203 A PH 27203A
- Authority
- PH
- Philippines
- Prior art keywords
- preparation
- strain
- strains
- treatment
- pharmaceutical preparation
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 22
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 9
- 206010044008 tonsillitis Diseases 0.000 title description 14
- 238000002360 preparation method Methods 0.000 claims description 21
- 206010044013 Tonsillitis streptococcal Diseases 0.000 claims description 11
- 244000005700 microbiome Species 0.000 claims description 10
- 229930182555 Penicillin Natural products 0.000 claims description 9
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 9
- 229940049954 penicillin Drugs 0.000 claims description 9
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 241000194023 Streptococcus sanguinis Species 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 241001134658 Streptococcus mitis Species 0.000 claims description 3
- 230000035899 viability Effects 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 235000010582 Pisum sativum Nutrition 0.000 claims 1
- 240000004713 Pisum sativum Species 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 8
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- 241000194017 Streptococcus Species 0.000 description 6
- 230000000306 recurrent effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108010062877 Bacteriocins Proteins 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 235000003332 Ilex aquifolium Nutrition 0.000 description 2
- 241000209027 Ilex aquifolium Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229930195708 Penicillin V Natural products 0.000 description 2
- 206010061372 Streptococcal infection Diseases 0.000 description 2
- 206010001093 acute tonsillitis Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229940056367 penicillin v Drugs 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000706896 Barteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920001393 Crofelemer Polymers 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000640813 Homo sapiens Sodium-coupled neutral amino acid transporter 2 Proteins 0.000 description 1
- 101100490849 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) alg-2 gene Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 102100033774 Sodium-coupled neutral amino acid transporter 2 Human genes 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940014946 minidrops Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/885—Streptococcus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8900510A SE463349B (sv) | 1989-02-15 | 1989-02-15 | Farmaceutiskt preparat foer profylax mot och/eller behandling av beta-streptokockinducerad tonsillit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH27203A true PH27203A (en) | 1993-05-04 |
Family
ID=20375049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH40021A PH27203A (en) | 1989-02-15 | 1990-02-08 | A pharmaceutical preparation in the treatment of tonsilitis |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US5378459A (de) |
| EP (1) | EP0458855B1 (de) |
| CN (1) | CN1046099A (de) |
| AR (1) | AR247099A1 (de) |
| AT (1) | ATE142503T1 (de) |
| AU (1) | AU628493B2 (de) |
| CA (1) | CA2047189A1 (de) |
| CS (1) | CS74890A2 (de) |
| DD (1) | DD291926A5 (de) |
| DE (1) | DE69028520T2 (de) |
| DK (1) | DK0458855T3 (de) |
| EG (1) | EG19075A (de) |
| ES (1) | ES2091818T3 (de) |
| FI (1) | FI101452B1 (de) |
| GR (1) | GR1000639B (de) |
| HU (1) | HU209915B (de) |
| IE (1) | IE900459L (de) |
| IL (1) | IL93242A (de) |
| IS (1) | IS1678B (de) |
| MY (1) | MY106487A (de) |
| NO (1) | NO178883C (de) |
| NZ (1) | NZ232381A (de) |
| PH (1) | PH27203A (de) |
| PT (1) | PT93141A (de) |
| SE (1) | SE463349B (de) |
| WO (1) | WO1990009186A1 (de) |
| YU (1) | YU23490A (de) |
| ZA (1) | ZA90692B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5705152A (en) * | 1990-10-26 | 1998-01-06 | Interprise Limited | Antimicrobial composition |
| AUPN698495A0 (en) * | 1995-12-06 | 1996-01-04 | Pharma Pacific Pty Ltd | Improved therapeutic formulation and method |
| SE511648C2 (sv) * | 1998-04-17 | 1999-11-01 | Bacterum Ab | Streptokockpreparat för behandling av öroninflammation |
| RU2279481C2 (ru) | 1999-10-12 | 2006-07-10 | Блис Текнолоджис Лимитед | Лантибиотик |
| DE10139039A1 (de) * | 2001-08-08 | 2003-05-08 | Zinon Douvlis | Medikamentöse Suppression maligner Proliferationsprozesse durch Aminosäuren und Aminosäurenbindungen orientierte Reaktionen |
| US20110256179A1 (en) | 2008-11-17 | 2011-10-20 | Essum Ab | Pharmaceutical preparation comprising a combination of streptococcus strains and lactobacillus strains |
| CN108135200B (zh) | 2015-10-01 | 2022-06-28 | 多伦多大学管理委员会 | 铁强化茶制品 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1195613A (en) * | 1981-02-17 | 1985-10-22 | Forsyth Dental Infirmary For Children | Method of treating periodontosis |
| US4454109A (en) * | 1981-02-17 | 1984-06-12 | Forsyth Dental Infirmary For Children | Method of treating periodontosis |
| JPS5927833A (ja) * | 1982-08-06 | 1984-02-14 | Advance Res & Dev Co Ltd | コレステロール乃至トリグリセリド低下剤 |
-
1989
- 1989-02-15 SE SE8900510A patent/SE463349B/sv not_active IP Right Cessation
-
1990
- 1990-01-30 ZA ZA90692A patent/ZA90692B/xx unknown
- 1990-02-01 IL IL9324290A patent/IL93242A/en not_active IP Right Cessation
- 1990-02-05 NZ NZ232381A patent/NZ232381A/en unknown
- 1990-02-07 YU YU23490A patent/YU23490A/sh unknown
- 1990-02-08 PH PH40021A patent/PH27203A/en unknown
- 1990-02-09 IE IE900459A patent/IE900459L/xx unknown
- 1990-02-12 AU AU51577/90A patent/AU628493B2/en not_active Ceased
- 1990-02-12 DE DE69028520T patent/DE69028520T2/de not_active Expired - Fee Related
- 1990-02-12 DK DK90903444.9T patent/DK0458855T3/da active
- 1990-02-12 ES ES90903444T patent/ES2091818T3/es not_active Expired - Lifetime
- 1990-02-12 CA CA002047189A patent/CA2047189A1/en not_active Abandoned
- 1990-02-12 WO PCT/SE1990/000089 patent/WO1990009186A1/en active IP Right Grant
- 1990-02-12 EP EP90903444A patent/EP0458855B1/de not_active Expired - Lifetime
- 1990-02-12 HU HU901920A patent/HU209915B/hu not_active IP Right Cessation
- 1990-02-12 AT AT90903444T patent/ATE142503T1/de not_active IP Right Cessation
- 1990-02-12 GR GR900100092A patent/GR1000639B/el unknown
- 1990-02-13 EG EG7290A patent/EG19075A/xx active
- 1990-02-14 IS IS3547A patent/IS1678B/is unknown
- 1990-02-14 PT PT93141A patent/PT93141A/pt not_active Application Discontinuation
- 1990-02-14 DD DD90337852A patent/DD291926A5/de unknown
- 1990-02-15 MY MYPI90000256A patent/MY106487A/en unknown
- 1990-02-15 CN CN90101773A patent/CN1046099A/zh active Pending
- 1990-02-15 AR AR90316173A patent/AR247099A1/es active
- 1990-02-15 CS CS90748A patent/CS74890A2/cs unknown
-
1991
- 1991-08-13 NO NO913162A patent/NO178883C/no not_active IP Right Cessation
- 1991-08-14 FI FI913845A patent/FI101452B1/fi active
-
1994
- 1994-02-10 US US08/194,753 patent/US5378459A/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Knox | A new penicillin (BRL 1241) active against penicillin-resistant staphylococci | |
| WO2000010582A2 (en) | Probiotic, lactic acid-producing bacteria and uses thereof | |
| KR102403453B1 (ko) | 헬리코박터 파이로리 감염의 관리를 위한 조성물 | |
| Meyers et al. | Microbiological and pharmacological behavior of 7-chlorolincomycin | |
| Sprunt et al. | The use of bacterial interference to prevent infection | |
| Frénay et al. | Long-term carriage, and transmission of methicillin-resistant Staphylococcus aureus after discharge from hospital | |
| Sharquie et al. | The antibacterial activity of tea in vitro and in vivo (in patients with impetigo contagiosa) | |
| PH27203A (en) | A pharmaceutical preparation in the treatment of tonsilitis | |
| CN109985069B (zh) | 益生菌组合物及其用途 | |
| Aly et al. | Bacterial interference among Staphylococcus aureus strains | |
| Van Saene et al. | Quinolones and colonization resistance in human volunteers | |
| Francioli et al. | Successful prophylaxis of experimental streptococcal endocarditis with single doses of sublethal concentrations of penicillin | |
| Safak et al. | In vitro anti‐Helicobacter pylori activity of usnic acid | |
| Pastor et al. | In-vitro postantibiotic effect of sparfloxacin and ciprofloxacin against Pseudomonas aeruginosa and Enterococcus faecalis | |
| Olds et al. | Amphotericin B-induced resistance to Schistosoma mansoni. | |
| Weinberger et al. | Prosthetic valve endocarditis caused by Acinetobacter calcoaceticus subsp. lwoffi | |
| Orenstein et al. | Antibiotic treatment of acute shigellosis: failure of cefamandole compared with trimethoprim/sulfamethoxazole and ampicillin | |
| Brook | In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities | |
| Sanford et al. | Oxolinic acid in the treatment of typhoid fever due to chloramphenicol-resistant strains of Salmonella typhi | |
| Sutherland | Spiramycin: a reappraisal of its antibacterial activity | |
| Brook et al. | The treatment of irradiated mice with polymicrobial infection caused by Bacteroides fragilis and Escherichia coli | |
| Styrt et al. | Granulocyte plasma membrane damage by leukotoxic supernatant from Pasteurella haemolytica A1 and protection by immune serum. | |
| Johny et al. | Antimicrobial treatment of Flavobacterium meningosepticum infection | |
| Smith et al. | Roxithromycin as a possible agent for prophylaxis of endocarditis: a study in normal volunteers | |
| Brook | Intra-abdominal Abscess In Children: A 13-Year Experience |